DiscGenics’ Japanese clinical trial of DDD cell therapy treats first patients

DiscGenics is engaged in developing regenerative cell-based therapies to relieve pain and reinstate function in patients with degenerative diseases of the spine. DiscGenics, a clinical stage biotechnology company, announced the first patients have been treated in its Japanese safety study, a clinical trial of Injectable Disc Cell Therapy (IDCT) for mild to moderate degenerative disc disease (DDD).
Full Article
Comments
Loading Feed
ChiefBacker
3y
Whichever company can successfully develop this type of technology with long-term results will help tens of millions of people year avoid pain and future surgeries. I'm rooting for every company in this space right now.I hope they all get it right.